Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Aprepitant

Aprepitant

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Aprepitant

38 trials tracked of Aprepitant: 11 in phase 3 or 4 and 1 with published results. The most-cited published study has 8 citations.

38Trials tracked
11Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 4 Phase 3 7 Phase 2 14 Phase 1 1 Other / NA 12
  1. Phase 3 Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data Completed · 8 cited
  2. Phase 4 A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) Completed
  3. Phase 4 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed
  4. Phase 4 Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting Completed
  5. Phase 4 Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. Completed
  6. Phase 3 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed
Show 32 more trials
  1. Phase 3 Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Completed
  2. Phase 3 A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed
  3. Phase 3 Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) Completed
  4. Phase 3 Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED) Completed
  5. Phase 3 Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting Completed
  6. Phase 2 Topical Aprepitant in Prurigo Patients Completed
  7. Phase 2 The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD Completed
  8. Phase 2 Ondansetron Versus Aprepitant Plus Ondansetron for Emesis Completed
  9. Phase 2 Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy Completed
  10. Phase 2 Phase 2 Bunionectomy HTX-011 Administration Study Completed
  11. Phase 2 Multi-day Doses in Prevention of Nausea and Emesis Completed
  12. Phase 2 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Completed
  13. Phase 2 Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy Completed
  14. Phase 2 Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide Completed
  15. Phase 2 Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer Completed
  16. Phase 2 Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX Completed
  17. Phase 2 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence Completed
  18. Phase 2 Treatment for Cannabis Withdrawal and Dependence Completed
  19. Phase 2 A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) Completed
  20. Phase 1 A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148) Completed
  21. N/A A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis Completed
  22. N/A The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing Completed
  23. N/A Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant Completed
  24. N/A Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant Completed
  25. N/A Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting Completed
  26. N/A Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients Completed
  27. N/A Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure Completed
  28. N/A Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) Completed
  29. N/A Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting Completed
  30. N/A Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed
  31. N/A Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis Completed
  32. N/A Differentiating the Effects of Substance P and Beta-endorphin Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.